Crucell Announces PER.C6 and AdVac Technology License Agreement with Wyeth Pharmaceuticals

31-Jul-2007

Crucell N.V. announced that it has entered into a co-exclusive PER.C6® and Advac® technology license agreement with Wyeth Pharmaceuticals, a division of Wyeth.

Under the terms of the agreement, Crucell will receive an upfront payment, milestone payments, annual maintenance fees, and royalties on net product sales. Other financial details were not disclosed.

Crucell's AdVac® technology is a recombinant vector technology used to develop novel adenoviral-based products. PER.C6® technology is based on a human cell line developed for the large-scale manufacture of biological products including vaccines.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...